Le Lézard
Classified in: Health, Science and technology
Subject: FVT

Avidity Biosciences to Participate in Upcoming Investor Conferences


SAN DIEGO, March 27, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCstm), today announced that Avidity management will be participating in the following upcoming conferences:

A live webcast of each of the events, up-to-date event details and archived replays will be available on the "Events and Presentations" page in the "Investors" section of Avidity's website at https://aviditybiosciences.investorroom.com/events-and-presentations.

About Avidity 
Avidity Biosciences, Inc.'s mission is to profoundly improve people's lives by delivering a new class of RNA therapeutics - Antibody Oligonucleotide Conjugates (AOCstm). Avidity is revolutionizing the field of RNA with its proprietary AOCs, which are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Utilizing its proprietary AOC platform, Avidity demonstrated the first-ever successful targeted delivery of RNA into muscle and is leading the field with clinical development programs for three rare muscle diseases: myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). Avidity is broadening the reach of AOCs with its advancing and expanding pipeline including programs in cardiology and immunology through internal discovery efforts and key partnerships. Avidity is headquartered in San Diego, CA. For more information about our AOC platform, clinical development pipeline and people, please visit www.aviditybiosciences.com and engage with us on LinkedIn and X.

Investor Contact:
Geoffrey Grande, CFA
(619) 837-5014
[email protected]

SOURCE Avidity Biosciences, Inc.


These press releases may also interest you

at 11:59
MGI Showcases Life Science Excellence at ESCMID Global 2024 with Latest DNBSEQ-E25 Sequencer and New Partnership with ABL Diagnostics
MGI Tech (MGI), a company committed to building core tools and technology to lead life science, today introduced the latest addition to its range of sequencers, the portable and easy-to-use DNBSEQ-E25 platform, for the European and African market. In...

at 11:46
Single Pass, Inc. Announces FDA Clearance of its Kronos Biopsy Closure Device
Single Pass, Inc. is proud to announce that its Class II Kronos biopsy closure device has received clearance from the U.S. Food and Drug Administration (FDA). The FDA has determined the device is substantially equivalent to predicate devices...

at 11:40
Government of Canada Supports Roger Neilson Children's Hospice's Project: Enhancing Access to Pediatric Palliative Care
Everyone in Canada deserve access to the care they need, when they need it most, including children and youth. Palliative care helps improve the quality of life, comfort, and resilience of seriously ill patients and their families, and is a critical...

at 11:35
Trella Health Announces Kathy Ford as Chief Product Officer, Advancing Ongoing Product Innovation and Expansion Initiatives
Trella Health, the leading provider of market intelligence and integrated customer relationship management (CRM) solutions to the post-acute care industry, is excited to announce the addition of Kathy Ford to its executive leadership team as Chief...

at 11:30
80 Percent of U.S. Women Say the Nation Faces a Retirement Crisis
Eighty percent of working age American women believe that the U.S. faces a retirement crisis, and 78 percent say the typical worker just can't save enough on their own to guarantee a secure retirement according to a new research infographic from the...

at 11:30
Prevent Blindness Announces Recipients of the 2024 Jenny Pomeroy Award for Excellence in Vision and Public Health, and the Rising Visionary Award
Prevent Blindness, the nation's leading eye health and safety organization, has announced the recipient of the 2024 Jenny Pomeroy Award for Excellence in Vision and Public Health as Mission for Vision (MFV). Erica Shelton, OD, MS, FAAO, Clinical...

More news about Health...


News published on and distributed by: